Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin for Osteosarcopenia
NCT04021706Phase 1Completed
- Sponsor
- Tufts University
- Start
- Dec 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteosarcopenia (OS) comparing Anamorelin with Placebo (2 arms). Primary endpoint: Total Body Muscle Mass by D3-creatine dilution at 12 months. Started Dec 2019; status: completed.
02
Drugs
anamorelin
03
Conditions
osteosarcopenia (OS)
Beyond the preview
Go deeper on NCT04021706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021706.